Recent Developments: Initiated Phase 3 trials for maritide (caftaglutide), targeting both GLP-1 and GIP receptors
your provider will follow the appropriate clinical protocols to start you at the lowest dose and move up as needed
Reduces Postprandial Glucose Spikes: By slowing gastric emptying, GLP-1 ensures that nutrients are absorbed gradually rather than rapidly
Available from: Jeevanandam J, San Chan Y, Danquah MK
Eli Lilly and Company Headquarters: Indianapolis, Indiana, United States Eli Lilly and Company is a global pharmaceutical company, kind of known for its strong attention to diabetes, obesity, and metabolic disorders, more or less
Glucagon-like peptide-1 (GLP-1) receptor agonists are medications approved by the FDA for managing type 2 diabetes and, in some formulations, for chronic weight management